Related Experiment Video
Updated: Apr 19, 2026
07:02
Animal Model of Implant-Associated Infections in Mice
Published on: June 27, 2025
1.2K
Lysostaphin-coated titan-implants preventing localized osteitis by Staphylococcus aureus in a mouse model
Ceylan D Windolf1, Tim Lögters1, Martin Scholz2
1Department of Trauma- and Hand Surgery, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.
Plos One
|December 24, 2014
Summary
Lysostaphin-coated implants effectively combat Staphylococcus aureus bone infections. This novel strategy promotes fracture healing and reduces inflammation, offering a promising solution for implant-associated infections.
Area of Science:
- Biomaterials Science
- Infectious Diseases
- Orthopedic Surgery
Background:
- Implant-associated infections caused by Staphylococcus aureus are increasing.
- Antibiotic resistance necessitates novel therapeutic approaches for bone infections.
Purpose of the Study:
- To evaluate the efficacy of lysostaphin-coated implants in treating Staphylococcus aureus bone infections.
- To assess the impact of lysostaphin coating on fracture healing and local immune response.
Main Methods:
- A mouse model of implant-associated bone infection was used.
- Lysostaphin-coated titanium plates (with PDLLA matrix) were compared to uncoated controls.
- Bacterial load, immune response, and fracture healing were assessed over 28 days.
Main Results:
- Lysostaphin-coated plates significantly reduced bacterial growth by Day 7.
- Complete fracture healing was observed by Day 28 in lysostaphin-treated groups.
- Control groups developed osteitis and significant local immune reactions.
Conclusions:
- Terminally sterilized lysostaphin-coated implants are a promising therapeutic for bone infections.
- This approach may be beneficial for treating low-grade infections or as prophylaxis in high-risk patients.
- Lysostaphin coating promotes fracture healing and mitigates adverse immune responses.
